In Brief This Week: Cepheid; BD; Transgenomic; Synthetic Genomics; Genetic Technologies; BioTime; Kiyatec; ABL | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid this week received CE marking for its Xpert CT/NG and Xpert CT tests, and the firm said it would begin shipping the tests in Europe immediately. The tests are for rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhea and run on Cepheid's GeneXpert System.


The Board of Directors of Becton Dickinson has declared a quarterly dividend of $.45 per share. The dividend is payable on June 29 to shareholders of record on June 8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.